{"acute myeloid leukaemia": 5.09, "agranulocytosis": 2.87, "anaemia": 5.14, "ascites": 2.8, "blood bilirubin increased": 2.07, "bone marrow failure": 4.36, "cholinergic syndrome": 157.05, "colitis": 4.65, "colorectal cancer metastatic": 80.85, "conjunctivitis": 2.95, "constipation": 3.14, "decreased appetite": 2.59, "dehydration": 2.92, "dermatitis acneiform": 32.34, "diarrhoea": 5.3, "disease progression": 8.41, "dry skin": 4.93, "dysarthria": 8.95, "ejection fraction decreased": 4.19, "febrile neutropenia": 15.13, "gastrointestinal toxicity": 44.85, "general physical health deterioration": 2.57, "haematotoxicity": 29.16, "hyperammonaemia": 19.91, "hyperbilirubinaemia": 3.39, "hypertransaminasaemia": 9.84, "hypokalaemia": 5.24, "hypomagnesaemia": 19.95, "interstitial lung disease": 2.37, "intestinal obstruction": 4.28, "leukopenia": 7.4, "malignant neoplasm progression": 3.06, "metastases to bone": 3.11, "metastases to liver": 12.28, "metastases to lung": 9.11, "metastases to lymph nodes": 6.79, "metastases to peritoneum": 23.87, "mucosal inflammation": 18.33, "myelodysplastic syndrome": 3.18, "myelosuppression": 8.73, "neoplasm progression": 2.35, "neuropathy peripheral": 9.7, "neurotoxicity": 17.46, "neutropenia": 23.16, "neutrophil count decreased": 8.76, "pancreatic carcinoma metastatic": 11.06, "pancytopenia": 2.79, "paronychia": 23.36, "peripheral sensory neuropathy": 21.02, "polyneuropathy": 3.27, "product use in unapproved indication": 2.47, "proteinuria": 4.36, "rash pustular": 8.67, "skin toxicity": 31.61, "stomatitis": 11.39, "therapeutic product effect incomplete": 2.58, "therapeutic response decreased": 2.1, "therapy partial responder": 14.8, "thrombocytopenia": 8.47, "toxicity to various agents": 3.63, "transaminases increased": 2.24, "vomiting": 2.69, "white blood cell count decreased": 4.13}